Avidity (RNA): Insider exercised 29,500 options and sold shares
Troy Edward Wilson, a director of Avidity Biosciences, Inc. (RNA), executed option exercises and share sales on 08/06/2025 under a previously adopted Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
Troy Edward Wilson, a director of Avidity Biosciences, Inc. (RNA), executed option exercises and share sales on 08/06/2025 under a previously adopted Rule 10b5-1 trading plan. He exercised 22,000 options at an exercise price of $12.03 and 7,500 options at $12.48, and sold shares at $45.00 per share pursuant to the plan.
Following the reported transactions the filing shows 69,425 shares held directly by the reporting person. The Form 4 also lists indirect beneficial ownership via several irrevocable trusts and a family trust, shown as 285,000, 285,000, 17,776, 17,776, 11,851, 11,851, and 13,711 shares. The filing states the 10b5-1 plan was adopted on December 4, 2024 and that all option shares were fully vested and exercisable at the time of exercise.
Positive
- Transactions executed under a Rule 10b5-1 plan, providing a preplanned framework for insider trades
- All option shares were fully vested and exercisable at the time of exercise, per the filing
Negative
- Multiple share sales at $45.00 on 08/06/2025 reduced the reporting person's direct holdings to 69,425 shares
- Large indirect holdings are held in several irrevocable trusts and a family trust, which may complicate consolidated ownership analysis
Insights
TL;DR Insider exercised vested options and sold shares under a 10b5-1 plan; direct holdings remain material.
The Form 4 reports option exercises of 22,000 and 7,500 shares at exercise prices of $12.03 and $12.48, respectively, with concurrent sales at $45.00 per share executed under a 10b5-1 plan adopted on 12/04/2024. The disclosure shows 69,425 shares held directly after the transactions and multiple blocks held indirectly via irrevocable and family trusts. This is a routine, preplanned liquidity event rather than an unplanned sale; it provides clear, itemized post-transaction ownership figures for investor review.
TL;DR Transactions were prearranged under a 10b5-1 plan and the filing confirms vesting status and trust-held indirect ownership.
The filing explicitly states the trades were effected pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2024, and that the option shares were fully vested and exercisable when exercised. The Form 4 also discloses several sizable indirect holdings held in named irrevocable trusts and a family trust, with the specific share counts listed. From a governance standpoint, the filing meets Section 16 transparency requirements by documenting the plan, exercise prices, sale price, and post-transaction beneficial ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 22,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 22,000 | $12.03 | $265K |
| Sale | Common Stock | 22,000 | $45.00 | $990K |
| Exercise | Common Stock | 7,500 | $12.48 | $94K |
| Sale | Common Stock | 7,500 | $45.00 | $338K |
| Sale | Common Stock | 15,000 | $45.00 | $675K |
| Sale | Common Stock | 15,000 | $45.00 | $675K |
| Sale | Common Stock | 17,777 | $45.00 | $800K |
| Sale | Common Stock | 17,777 | $45.00 | $800K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024.
- F2. All shares of common stock subject to this option were fully vested and exercisable as of the date of execution of this option by Reporting Person.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What trades did the Avidity (RNA) insider report on the Form 4?
Was the insider trading done under a trading plan for Avidity (RNA)?
Does the Form 4 disclose indirect ownership for Avidity (RNA)?
AI-generated analysis. How Rhea-AI works. Not financial advice.
